{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:47:50Z","timestamp":1785408470084,"version":"3.56.0"},"reference-count":103,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011640","name":"European Neuromuscular Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011640","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007393","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007393","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010275","name":"Deutsche Gesellschaft f\u00fcr Muskelkranke","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010275","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Muscular Dystrophy Campaign"},{"DOI":"10.13039\/501100011641","name":"Muskelsvindfonden","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011641","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Prinses Beatrix Fonds"},{"name":"Schweizerische Stiftung f\u00fcr die Erforschung der Muskelkrankheiten"},{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spierziekten Nederland"},{"name":"Finnish Neuromuscular Association"},{"name":"Myositis UK"},{"DOI":"10.13039\/100015391","name":"The Myositis Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015391","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"aTyr Pharmaceuticals"},{"name":"LFB Group"},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.nmd.2016.05.014","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T16:15:07Z","timestamp":1464452107000},"page":"523-534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18\u201320 September 2015"],"prefix":"10.1016","volume":"26","author":[{"given":"Olivier","family":"Benveniste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Allenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Benveniste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"De Bleecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Devilliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hilton-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-Y.","family":"Hogrel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Oakley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Padberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Selva- O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2016.05.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","author":"Allenbach","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2016.05.014_bib0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2016.05.014_bib0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.61.3.288","article-title":"Unicorns, dragons, polymyositis, and other mythological beasts","volume":"61","author":"Amato","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.05.014_bib0025","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"Van der Meulen","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.05.014_bib0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-015-1384-5","article-title":"Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken","author":"Benveniste","year":"2015","journal-title":"Acta Neuropathol (Berl)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.05.014_bib0045","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","author":"Betteridge","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.nmd.2016.05.014_bib0050","first-page":"S323","article-title":"Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies","author":"Tj\u00e4rnlund","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0055","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.05.014_bib0060","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0065","author":"U.S. Department of Health and Human Services, Food and Drug Administration"},{"key":"10.1016\/j.nmd.2016.05.014_bib0070","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1469-8749.2008.00408.x","article-title":"Watch out, watch out, the FDA are about","volume":"50","author":"Cano","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mus.20686","article-title":"Challenges in drug development for muscle disease: a stakeholders' meeting","volume":"35","author":"Mendell","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.05.014_bib0080","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/BOR.0b013e32833f8f72","article-title":"Neurologists are from Mars. Rheumatologists are from Venus: differences in approach to classifying the idiopathic inflammatory myopathies","volume":"22","author":"Christopher-Stine","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0085","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0090","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","article-title":"Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies","volume":"40","author":"Miller","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0095","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 11","key":"10.1016\/j.nmd.2016.05.014_bib0100","first-page":"S118","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2016.05.014_bib0105","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0889-857X(02)00027-3","article-title":"Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies","volume":"28","author":"Rider","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.nmd.2016.05.014_bib0110","first-page":"603","article-title":"Defining clinical improvement in adult and juvenile myositis","volume":"30","author":"Rider","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0115","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0125","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.nmd.2013.07.007","article-title":"ENMC myositis muscle biopsy study group. 193rd ENMC international workshop pathology diagnosis of idiopathic inflammatory myopathies 30 November-2 December 2012, Naarden, The Netherlands","volume":"23","author":"De Bleecker","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2016.05.014_bib0130","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC international workshop: pathology diagnosis of idiopathic inflammatory myopathies Part II 28\u201330 March 2014, Naarden, The Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2016.05.014_bib0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.nmd.2016.05.014_bib0140","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/brain\/awv192","article-title":"Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis","volume":"138","author":"Mescam-Mancini","year":"2015","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.nmd.2016.05.014_bib0145","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1212\/WNL.0000000000001422","article-title":"Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy","volume":"84","author":"Stenzel","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.nmd.2016.05.014_bib0150","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated protein 5 antibodies: common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0155","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3899\/jrheum.141443","article-title":"The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from patients with dermatomyositis","volume":"42","author":"Pinal-Fernandez","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0160","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0165","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.2010.1977","article-title":"Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies","volume":"305","author":"Rider","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2016.05.014_bib0175","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2016.05.014_bib0180","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0185","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/path.4346","article-title":"Altered RIG-I\/DDX58-mediated innate immunity in dermatomyositis","volume":"233","author":"Su\u00e1rez-Calvet","year":"2014","journal-title":"J Pathol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0190","article-title":"Anti-MDA5 is associated with rapidly progressive lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis","author":"Moghadam-Kia","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2016.05.014_bib0195","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0200","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0205","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","article-title":"Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial","volume":"387","author":"Ruperto","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2016.05.014_bib0210","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.nmd.2013.06.714","article-title":"P.21.9 Responsiveness of muscle testing and functions in a retrospective 51 inflammatory myopathies patient series","volume":"23","author":"Devilliers","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2016.05.014_bib0215","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/brain\/awr318","article-title":"Modifying the Medical Research Council grading system through Rasch analyses","volume":"135","author":"Vanhoutte","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2016.05.014_bib0220","article-title":"Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2016.05.014_bib0225","article-title":"Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial","volume":"10","author":"Seferian","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2016.05.014_bib0230","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.nmd.2012.05.004","article-title":"Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis","volume":"22","author":"Allenbach","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2016.05.014_bib0235","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.nmd.2014.04.009","article-title":"Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: implications for therapeutic trials","volume":"24","author":"Hogrel","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2016.05.014_bib0240","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2016.05.014_bib0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/mus.20958","article-title":"Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity","volume":"37","author":"Jackson","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.05.014_bib0250","doi-asserted-by":"crossref","first-page":"S310","DOI":"10.1016\/j.nmd.2015.06.442","article-title":"Wrist-worn accelerometer as innovative tool for longitudinal follow-up of idiopathic inflammatory myopathy patients: a pilot study","volume":"25","author":"Allenbach","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2016.05.014_bib0260","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2016.05.014_bib0265","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0270","first-page":"689","article-title":"Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial","volume":"32","author":"Rider","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0275","first-page":"2386","article-title":"Development of the myositis activities profile \u2013 validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis\/dermatomyositis","volume":"29","author":"Alexanderson","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/rheumatology\/keh404","article-title":"Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis","volume":"44","author":"Ponyi","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0285","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.20179","article-title":"Validation and clinical significance of the childhood myositis assessment scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies","volume":"50","author":"Huber","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0290","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/art.23248","volume":"59","author":"Ruperto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0295","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/art.21715","article-title":"Functional index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis","volume":"55","author":"Alexanderson","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0300","first-page":"S324","article-title":"Validation of the Functional Index 3 in polymyositis and dermatomyositis","author":"Ernste","year":"2012","journal-title":"Arthritis Rheumatol Suppl"},{"key":"10.1016\/j.nmd.2016.05.014_bib0305","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.24093","article-title":"Activity rating scales in adult muscle disease: what do they actually measure?","volume":"50","author":"Seedat","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.05.014_bib0310","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/mus.24090","article-title":"Activity rating scales in adult muscle disease: how well do they actually measure?","volume":"50","author":"Seedat","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.05.014_bib0315","first-page":"S404","article-title":"A consensus hybrid definition using a conjoint analysis is the proposed as response criteria for minimal and moderate improvement for adult polymyositis and dermatomyositis clinical trials","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol Suppl"},{"key":"10.1016\/j.nmd.2016.05.014_bib0320","first-page":"S578","article-title":"A hybrid conjoint analysis model is proposed as the definition of minimal, moderate and major clinical improvement in juvenile dermatomyositis clinical trials","author":"Rider","year":"2014","journal-title":"Arthritis Rheumatol Suppl"},{"key":"10.1016\/j.nmd.2016.05.014_bib0325","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1477-7525-9-114","article-title":"Validation of the individualised neuromuscular quality of life for the USA with comparison of the impact of muscle disease on those living in USA versus UK","volume":"9","author":"Sadjadi","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.nmd.2016.05.014_bib0330","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1468-1331.2010.02992.x","article-title":"Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases","volume":"17","author":"Sansone","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0335","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0340","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1002\/art.23963","article-title":"Reliability and validity of the myositis disease activity assessment tool","volume":"58","author":"Sultan","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0345","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/thoraxjnl-2013-204202","article-title":"Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials","volume":"69","author":"Saketkoo","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.nmd.2016.05.014_bib0350","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0355","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0360","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","author":"Robinson","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0365","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0370","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.3899\/jrheum.141243","article-title":"Patients' experience of myositis and further validation of a myositis-specific patient reported outcome measure \u2013 establishing core domains and expanding patient input on clinical assessment in myositis. Report from OMERACT 12","volume":"42","author":"Regardt","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0375","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10067-014-2685-0","article-title":"Health-related quality of life and well-being in adults with idiopathic inflammatory myopathy","volume":"33","author":"Armadans-Tremolosa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0380","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0385","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1136\/ard.2010.142117","article-title":"Interrater reliability and aspects of validity of the myositis damage index","volume":"70","author":"Sultan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2016.05.014_bib0390","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2016.05.014_bib0395","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2016.05.014_bib0400","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2016.05.014_bib0405","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.nmd.2016.05.014_bib0410","first-page":"S55","article-title":"Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials","volume":"28","author":"Khanna","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0415","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1183\/09031936.00155108","article-title":"Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis","volume":"35","author":"Zappala","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2016.05.014_bib0420","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/jid.2011.440","article-title":"Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM","volume":"132","author":"Goreshi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0425","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.23313","article-title":"Juvenile dermatomyositis disease activity collaborative study group. Alternative scoring of the cutaneous assessment tool in juvenile dermatomyositis: results using abbreviated formats","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0430","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/art.23340","article-title":"Preliminary validation and clinical meaning of the cutaneous assessment tool in juvenile dermatomyositis","volume":"59","author":"Huber","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.nmd.2016.05.014_bib0435","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0440","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/ar4198","article-title":"Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms?","volume":"15","author":"Tansley","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.nmd.2016.05.014_bib0445","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0450","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1093\/rheumatology\/keu146","article-title":"Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool","volume":"53","author":"Sanner","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0455","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/acr.21637","article-title":"Quality of life in adults with juvenile-onset dermatomyositis: a case-control study","volume":"64","author":"Tollisen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2016.05.014_bib0460","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/acr.20203","article-title":"Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study","volume":"62","author":"Sanner","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2016.05.014_bib0465","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/ard.2010.131433","article-title":"Pulmonary outcome in juvenile dermatomyositis: a case-control study","volume":"70","author":"Sanner","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2016.05.014_bib0470","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/ard.2010.137968","article-title":"Cardiac dysfunction in juvenile dermatomyositis: a case-control study","volume":"70","author":"Schwartz","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2016.05.014_bib0475","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1136\/annrheumdis-2013-203279","article-title":"In juvenile dermatomyositis, cardiac systolic dysfunction is present after long-term follow-up and is predicted by sustained early skin activity","volume":"73","author":"Schwartz","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2016.05.014_bib0480","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1136\/ard.2005.045690","article-title":"Long-term outcome in polymyositis and dermatomyositis","volume":"65","author":"Bronner","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmd.2016.05.014_bib0485","first-page":"447","article-title":"A comparative study of outcome in myositis and other musculoskeletal disorders assessed using the Nottingham health profile","volume":"19","author":"Chung","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0490","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/rheumatology\/keq356","article-title":"Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study","volume":"50","author":"Regardt","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nmd.2016.05.014_bib0495","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/rheumatology\/41.1.22","article-title":"Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality","volume":"41","author":"Sultan","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 11","key":"10.1016\/j.nmd.2016.05.014_bib0500","first-page":"S383","volume":"63","author":"Busija","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2016.05.014_bib0505","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/01.wnl.0000257819.47628.41","article-title":"Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL)","volume":"68","author":"Vincent","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2016.05.014_bib0510","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ane.12173","article-title":"Dependent and paranoid personality patterns in myotonic dystrophy type 1","volume":"129","author":"Peric","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2016.05.014_bib0515","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/mus.24337","article-title":"The individualized neuromuscular quality of life questionnaire: cultural translation and psychometric validation for the Dutch population","volume":"51","author":"Seesing","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2016.05.014_bib0520","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00415-014-7313-z","article-title":"Long-term follow-up of 62 patients with myositis","volume":"261","author":"Van de Vlekkert","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2016.05.014_bib0525","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/acr.22068","article-title":"Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup","volume":"65","author":"Alemo Munters","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2016.05.014_bib0530","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3899\/jrheum.131247","article-title":"Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 myositis special interest group","volume":"41","author":"Alexanderson","year":"2014","journal-title":"J Rheumatol"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616302000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616302000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:04:28Z","timestamp":1760774668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896616302000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0960896616302000"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2016.05.014","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18\u201320 September 2015","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2016.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}